XENT News and Press, Intersect ENT Inc. From 11/02/20

Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the third quarter ended September 30, 2020. Third Quarter 2020 Overview Revenue of $22.7 million in...

[[AMCX]], [[BWXT]], [[CDW]], [[CLX]], [[CNA]], [[CWH]], [[DEA]], [[EL]], [[FE]], [[HLIO]], [[HSIC]], [[HZNP]], [[IAA]], [[INGR]], [[ITRI]], [[JLL]], [[LCII]], [[LDOS]], [[LITE]], [[LL]], [[MGP]], [[MPC]], [[MPLX]], [[MSGN]], [[NI]], [[NNN]], [[NSP]], [[TEN]], [[USFD]], [[WING]], [[WM]], [[XEN...

Intersect ENT (XENT) expects Q3 revenue to be $22.4M-22.8M.SINUVA expected to achieve strongest quarterly revenue to date of ~$1.7M.Cash and marketable securities are expected to be ~$130M.Thomas A. West, President and CEO comments: "Our solid third quarter preliminary revenue reflects a cont...

Preliminary Third Quarter 2020 Revenue Expected to be $22.4 to $22.8 Million Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced preliminary third quarter 2020 revenue and provid...

Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it will release third quarter 2020 financial results on November 2, 2020. The Company expects to issue the release at approximate...

Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced it closed the previously announced transaction to acquire Fiagon AG Medical Technologies , a leader in electromagnetic surgica...

Intersect ENT (NASDAQ: XENT ) has agreed to acquire  Fiagon, a provider of electromagnetic surgical navigation solutions, for €60M More news on: Intersect ENT, Inc., Healthcare stocks news, Merger & acquisition news, Read more ...

Novel navigation technology and recently FDA-cleared sinuplasty balloon expand Intersect ENT’s commercial product portfolio Extends Intersect ENT’s footprint in U.S. and European ENT physicians’ offices Intersect ENT, Inc. (Nasdaq: XENT), a company transformi...

Intersect ENT ( XENT +4.3% ) has executed a pharmacy services agreement with AllianceRx Walgreens Prime for national specialty pharmacy distribution of the Company’s SINUVA (mometasone furoate) Sinus Implant. More news on: Intersect ENT, Inc., Healthcare stocks news, Re...

Agreement expands patient access to SINUVA treatment with announcement of third partnership with a specialty pharmacy Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (ENT) conditions, today announced that it has executed a pharmac...